Summary:
Interventional Efficacy and Safety, Phase 2/3,Randomized, Double-Blind, 2-Arm Study to Investigate Orally Administered PF-07321332/ritonavir Compared with Placebo in NonHospitalized Symptomatic Adult Participants with COVID-19 at Low Risk of Progressing to Severe Illness.
Criteria:
- Males or females ≥18 to ≤59 years of age
- Confirmed SARS-CoV-2 infection as determined by RT-PCR in any specimen collected within 72 hours prior to randomization.
- Has mild or moderate COVID-19 andis non-hospitalized
- Has no characteristic or medical condition associated with an increased risk of severe illness from COVID-19